Ann Lab Med.  2023 Jan;43(1):3-4. 10.3343/alm.2023.43.1.3.

Cost-effective BRCA Testing in Advanced Ovarian Cancer

• Kim M

• KMID: 2551568
• DOI: http://doi.org/10.3343/alm.2023.43.1.3

Reference

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68:394–424. DOI: 10.3322/caac.21492. PMID: 30207593.

2. Park B, Park S, Kim TJ, Ma SH, Kim BG, Kim YM, et al. 2010; Epidemiological characteristics of ovarian cancer in Korea. J Gynecol Oncol. 21:241–7. DOI: 10.3802/jgo.2010.21.4.241. PMID: 21278886. PMCID: PMC3026303.

3. Hunn J, Rodriguez GC. 2012; Ovarian cancer: etiology, risk factors, and epidemiology. Clin Obstet Gynecol. 55:3–23. DOI: 10.1097/GRF.0b013e31824b4611. PMID: 22343225.

4. Jung KW, Won YJ, Kong HJ, Lee ES. 2019; Prediction of cancer incidence and mortality in Korea, 2019. Cancer Res Treat. 51:431–7. DOI: 10.4143/crt.2019.139. PMID: 30913864. PMCID: PMC6473283.

5. Wright JD, Chen L, Tergas AI, Patankar S, Burke WM, Hou JY, et al. 2015; Trends in relative survival for ovarian cancer from 1975 to 2011. Obstet Gynecol. 125:1345–52. DOI: 10.1097/AOG.0000000000000854. PMID: 26000505. PMCID: PMC4484269.

6. George A, Kaye S, Banerjee S. 2017; Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer. Nat Rev Clin Oncol. 14:284–96. DOI: 10.1038/nrclinonc.2016.191. PMID: 27958297.

7. Colombo N, Huang G, Scambia G, Chalas E, Pignata S, Fiorica J, et al. 2018; Evaluation of a streamlined oncologist-led BRCA mutation testing and counseling model for patients with ovarian cancer. J Clin Oncol. 36:1300–7. DOI: 10.1200/JCO.2017.76.2781. PMID: 29558274. PMCID: PMC6804908.

8. Lee A, Moon BI, Kim TH. 2020; BRCA1/BRCA2 pathogenic variant breast cancer: treatment and prevention strategies. Ann Lab Med. 40:114–21. DOI: 10.3343/alm.2020.40.2.114. PMID: 31650727. PMCID: PMC6822003.

9. Lee A, Kang J, Lee H, Lee YS, Choi YJ, Lee KH, et al. 2019; BRCA1/2 somatic mutation detection in formalin-fixed paraffin embedded tissue by next-generation sequencing in Korean ovarian cancer patients. Pathol Res Pract. 215:152595. DOI: 10.1016/j.prp.2019.152595. PMID: 31570282.

10. Yoo J, Lee GD, Kim JH, Lee SN, Chae H, Han E, et al. 2020; Clinical validity of next-generation sequencing multi-gene panel testing for detecting pathogenic variants in patients with hereditary breast-ovarian cancer syndrome. Ann Lab Med. 40:148–54. DOI: 10.3343/alm.2020.40.2.148. PMID: 31650731. PMCID: PMC6822011.

11. Jang J, Kim Y, Kim JH, Cho SM, Lee KA. 2023; Cost-Effectiveness Analysis of Germline and Somatic BRCA Testing in Patients with Advanced Ovarian Cancer. Ann Lab Med. 43:73–81. DOI: 10.3343/alm.2023.43.1.73. PMID: 36045059.